http://www.summitplc.com/
Summit is an Oxford, UK based drug discovery company developing novel drug candidates to treat areas of high unmet medical need. Our strategy has evolved to focus on the development of two high-value clinical-stage programmes that target the fatal genetic disease Duchenne Muscular Dystrophy (DMD) and infections caused by the superbug C. difficile

Nice to see the gradual increase in the SP continuing,,,,I've now doubled my outlay on this from when I went in April last year... I even bought it through the old Hoodless Brennan.. makes a change for an HP rec doesn't ?!... still staying though for time being.

Sold a few of these.

:-))

Yes - thanks for these - I bought in @5.5.

I owe you some well dones skinny, so well done on these. :-)) Lets hope they get back to the highs of the past.

Summit Corporation PLC (SUMM:LSE) set a new 52-week high during today's trading session when it reached 8.13. Over this period, the share price is up 160.00%.

:)

Closed up 10.77%.


Summit Corporation PLC (SUMM:LSE) set a new 52-week high during today's trading session when it reached 9.14. Over this period, the share price is up 204.65%.

Summit Corporation PLC : Notice of Interim Results

HUG


Summit Corporation plc
('Summit' or 'the Company')

NOTICE OF INTERIM RESULTS

Oxford, UK, 21 August 2013 - Summit (AIM: SUMM), a drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy ('DMD') and C. difficile infection, will announce its interim results for the six months ended 31 July 2013 on Thursday, 22 August 2013.

Summit Corporation PLC : Interim Financial Results

HUG


Summit Corporation plc
("Summit" or "the Company")

INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 JULY 2013

Oxford, UK, 22 August 2013, Summit (AIM: SUMM), a drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy and C. difficile infection, today reports its interim financial results for the six months ended 31 July 2013.

HIGHLIGHTS

Product Development



Duchenne Muscular Dystrophy ('DMD')
•
Phase 1b patient clinical trial of SMT C1100 on-track to start in H2 2013

•
Activities supporting clinical DMD programme progressing well and include the initiation of novel biomarker programme and drug product manufacture

•
Programme Advisory Board established to support scientific and clinical development of DMD programme


C. difficile Infection ('CDI')
•
Positive results from Phase 1 clinical trial in healthy volunteers showed novel antibiotic SMT 19969 to be safe and well tolerated in this study

•
Encouraging data from Phase 1 trial about future efficacy and specificity of SMT 19969 with results showing it was highly sparing of gut flora bacteria

•
Preparations to commence patient clinical trials in H1 2014 progressing well


Corporate
•
New funding secured from broad range of sources including £4.6 million fund raise with new and existing investors and £2.4 million grant from UK Biomedical Catalyst Fund

•
Dr Frank Armstrong appointed as Non-Executive Chairman with Dr Barry Price taking up a Non-Executive Director role

•
Strengthening of clinical development team including the appointment of Dr David Roblin as Chief Medical Officer


Financial
•
Cash position at 31 July 2013: £6.0 million (31 July 2012: £4.8 million)

•
Operational expenditure in-line with expectations

•
Net loss for the six months ended 31 July 2013 £2.1 million (31 July 2012: £2.2 million)


Glyn Edwards, Chief Executive Officer of Summit commented: "It has been an excellent period for Summit during which our strategy of focusing on the development of our clinical-stage DMD and C. difficile programmes has made substantial scientific progress and also received broad financial support."



"We now look forward to advancing clinical trials into patient populations for both the DMD and CDI programmes to further evaluate these potential life-changing treatments for two serious diseases."



- END

Nice! ..nothing new really but a good summary...onwards and upwards! what price in 12/18 months time ?

Summit entering exciting stage of its development
By John Harrington August 22 2013, 7:49am 'We now look forward to advancing clinical trials into patient populations for both the DMD and CDI programmes to further evaluate these potential life-changing treatments for two serious diseases,' said Glyn Edwards, chief executive officer of Summit."We now look forward to advancing clinical trials into patient populations for both the DMD and CDI programmes to further evaluate these potential life-changing treatments for two serious diseases," said Glyn Edwards, chief executive officer of Summit.

Summit (LON:SUMM), the high-flying drug discovery company, said the first half of its financial year had been an excellent period for the company.

On the product development front, the company’s phase 1b patient clinical trial of SMT C1100, its Duchenne Muscular Dystrophy (DMD) drug, is on track to start before the end of this year, while its novel antibiotic SMT 19969, for the treatment of C. difficile infection, saw positive results from its Phase 1 clinical trial in healthy volunteers, showing it to be safe and well-tolerated.

As is to be expected from a drug discovery and development company that is currently relying chiefly on grant and other not-for-profit funding for its revenue, the company made a loss in the six months to the end of July, but at £2.38mln this was virtually unchanged from the year before, despite spending on research & development rising to £2.08mln from £1.85mln.

Cash at the end of July stood at £6.0mln, up from £4.8mln a year earlier. The company said operational expenditure during the reporting period was in line with expectations.

“The company is entering an exciting stage in its development as our two programmes prepare to commence patient clinical trials. The promise these programmes are showing as life-changing treatments for two serious diseases is being endorsed externally by respected organisations that include the Biomedical Catalyst and the Wellcome Trust,” noted Glyn Edwards, chief executive officer of Summit.

Shares in Summit have doubled over the last month

Summit Corporation: N+1 Singer shifts target price from 8.80p to 10.70p keeping its buy recommendation

Looking good... I'm staying in for the long term..having got in @ 3.5p some while ago it's temting to take the profit but ....

2007 they were 120p.

Summit Granted Key Composition of Matter Patent...

HUG


Summit Corporation plc
('Summit' or 'the Company')

SUMMIT GRANTED KEY COMPOSITION OF MATTER PATENT FOR UTROPHIN MODULATOR SMT C1100 IN THE TREATMENT OF DMD

Oxford, UK, 28 August 2013 - Summit (AIM: SUMM), a drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy ('DMD') and C. difficile infection, announces that the United States Patent and Trademark Office has issued a composition of matter patent that protects SMT C1100 and its use in the treatment of the fatal muscle wasting disease DMD.

United States Patent number 8,518,980 is entitled "Treatment of Duchenne Muscular Dystrophy" and will provide a period of exclusivity for the small molecule utrophin modulator SMT C1100 through at least November 2028.

"The grant of this cornerstone patent for SMT C1100 in a key commercial market represents a critical component in our strategy for advancing this promising utrophin modulator in the treatment of DMD," commented Glyn Edwards, Chief Executive Officer of Summit. "Together with the recently issued US patent covering the use of SMT C1100 in combination with steroids, the intellectual property estate protecting this potential life-changing drug has been significantly strengthened as we prepare to start patient clinical trials during the second half of this year."

The patent "Drug Combinations for the Treatment of Duchenne Muscular Dystrophy" was recently issued by the US Patent and Trademark Officer and covers the use of SMT C1100 in combination with steroids such as prednisolone and deflazacort (US Patent number 8,501,713).

About DMD and SMT C1100
DMD is a progressive muscle wasting disease that affects around 1,500 boys and young men in the UK. It is caused by different genetic faults in the gene that encodes dystrophin, a protein that is essential for the healthy function of muscles. There is no cure and life expectancy is around the mid-twenties. Utrophin protein is the functional equivalent of dystrophin and non-clinical studies have shown it can substitute for dystrophin to maintain the healthy function of skeletal and cardiac muscle. Utrophin modulation has the potential to slow down or even stop the progression of DMD regardless of the dystrophin mutation. Importantly it is also expected to be complementary to other DMD therapeutic approaches in development. SMT C1100, an orally administered small molecule, is Summit's most advanced utrophin modulator and it is expected to start clinical trials in DMD patients during the second half of 2013.

- END -

More good patent news released this morning...who knows, in a couple of years time it could be worth 120p again !

Excellent news, some positive territory today!

Summit to Present New Data on C difficile Antib...

HUG


Summit Corporation plc
('Summit' or 'the Company')

SUMMIT TO PRESENT NEW DATA ON C. DIFFICILE ANTIBIOTIC PROGRAMME AT ICAAC 2013

Oxford, UK, 4 September 2013 - Summit (AIM: SUMM), a drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy and C. difficile infection ('CDI'), announces that clinical and preclinical data on its novel, selective antibiotic SMT19969 for the treatment of CDI will be reported in podium and poster presentations at the 53rd annual Interscience Conference on Antimicrobial Agents and Chemotherapy ('ICAAC') meeting in Denver, Colorado, USA from 10-13 September 2013.

Summit has been selected by an expert panel of the American Society for Microbiology to give an oral presentation summarising SMT19969 in the 'Early New Antimicrobial Agents Poster Summary Session', which will highlight the next wave of compounds with potential to move through the clinical development process. This presentation will feature Phase 1 clinical trial and preclinical data which will be included in five posters being reported by Summit and its key collaborators during the conference.

Glyn Edwards, Chief Executive Officer of Summit commented: "Summit is pleased to have been selected to showcase the data on our novel and selective antibiotic SMT19969 for the treatment of C. difficile infection at this major international conference."

Further details about the presentations are below and the full abstracts are available online at www.icaac.org/index.php/online-program-planner.

Tuesday 10 September 2013

Oral Presentation: Early New Antimicrobial Agents Poster Summary Session (2.30-4.30pm MDT)

SMT19969: A Selective Therapy for C. difficile Infection (R Vickers)

Poster Session 018: Clostridium difficile (12.00-2.00pm MDT)

K-167 Effects of a Novel Antimicrobial (SMT19969) for Treatment of Clostridium difficile Infection (CDI) on Gut Flora; EL Best, R Vickers, M Wilcox.

Wednesday 11 September 2013

Poster Session 082: Agents Acting Against Clostridium difficile (11:00am-1:00pm MDT)

F-624 Comparative in vitro Activity of SMT19969, a New Antimicrobial Agent, Against Clostridium difficile and 203 Gram-positive Aerobic and Anaerobic Gut Flora Isolates; EJ Goldstein, DM Citron.

F-625 SMT19969: Effects of Varying MIC Parameters on the in vitro activity against Clostridium difficile; A Wise, D Corbett, P Thommes, S Birchall, R Vickers, PA Warn.

F-626 SMT19969 for Clostridium difficile Infection (CDI): Phase 1 Study Investigating Safety and Pharmacokinetics in Healthy Male Subjects; R Vickers, N Robinson, E Best, M Wilcox, G Tillotson, R Echols.

F-631b Comparative in vitro activity of SMT19969, a new antimicrobial agent against 169 less common intestinal clostridium species: Implications for recurrence; EJC Goldstein, DM Citron.

Copies of these presentations will be available on the Summit website during the ICAAC meeting.

- END -

Trying 10p again.